Arcutis Biotherapeutics Inc. (ARQT) saw its stock surge 5.08% during Friday's trading session, propelled by the company's impressive quarterly performance and encouraging developments in its drug pipeline.
In its latest earnings report, Arcutis exceeded analyst expectations with a 6% beat on revenue and a narrower-than-expected loss per share. Buoyed by these results, analysts raised their 2025 revenue forecasts for the company by 4.6% to $301.8 million and lowered their projected loss per share by 19% to $0.60.
Adding to the positive sentiment, Arcutis announced that it will present data from two Phase 3 trials of its atopic dermatitis and psoriasis treatments, ZORYVE cream and ZORYVE foam, at the upcoming American Academy of Dermatology annual meeting. The data highlights the products' strong safety and tolerability profiles, as well as improvements in patient-reported outcomes, further bolstering their commercial prospects.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.